Credit: Phathom Pharmaceuticals. Vonoprazan is an oral small molecule potassium-competitive acid blocker. The Food and Drug Administration (FDA) has approved Voquezna (vonoprazan) for healing and ...

DelveInsight's, “Erosive Esophagitis Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Erosive Esophagitis pipeline landscape. It covers the ...

Detailed price information for Phathom Pharmaceuticals Inc (PHAT-Q) from The Globe and Mail including charting and trades.

throat The application is supported by data from the pivotal phase 3 PHALCON-EE trial which compared the efficacy and safety of vonoprazan to lansoprazole in patients with erosive esophagitis. The New ...

How Do I Take Voquezna? Voquezna is an oral tablet that is taken once daily for GERD or erosive esophagitis and twice daily for H. pylori. Voquezna can be taken with or without food. Your doctor will ...

BUFFALO GROVE, Ill.--(BUSINESS WIRE)-- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for ...

The oral potassium-competitive acid blocker (PCAB) vonoprazan was noninferior and superior to the proton pump inhibitor (PPI) lansoprazole for erosive esophagitis, according to results of the phase 3 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Phathom Pharmaceuticals’ Voquezna tablets 10 mg and 20 mg to treat erosive esophagitis, or ...

Los Angeles, CA – New clinical data demonstrated, for the first time in a prospective study, a direct relationship between controlling gastric (or stomach) acid and healing erosive esophagitis caused ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am 63 years old, and four weeks ago, I was diagnosed by my ...

In nearly 500,000 adults who underwent an endoscopy in Denmark, Finland, and Sweden, the incidence rate of esophageal adenocarcinoma was 11 per 100,000 person-years among those with non-erosive GERD, ...